LightNews — News, ranked by scholars

OncoDaily

@oncodaily.bsky.social

Enfortumab Vedotin (Padcev): Uses in Cancer, Side Effects, Dosage, Expectations, and More

oncodaily.com/drugs/enfort...

#AdvancedUrothelialCarcinoma #BladderCancer #Cancer #CancerTreatment #Drugs #FDAApproved #Medicine #Health #EnfortumabVedotin #OncoDaily #Oncology #Padcev #TargetTherapy

Enfortumab Vedotin (Padcev), Uses, side effects, expectation

Enfortumab Vedotin (Padcev) treats advanced urothelial cancer. Learn about its uses, dosage, side effects, and what to expect during treatment.

oncodaily.com

March 14, 2025 at 5:17 PM

MSK Library

@msklibrary.bsky.social

Synapse: Your Connection to our MSK Authors
Meet: Asia S McCoy
Research Focus: Nursing; Clinical Trials Nurse IV

#UrothelialCancer #EnfortumabVedotin #ImmunoOncology #CancerResearch #PBMC #BladderCancer #MetastaticCancer #TargetedTherapy #OncologyScience

synapse.mskcc.org/synapse/work...

July 10, 2025 at 4:04 PM

ScienceOpen

@scienceopen.bsky.social

'Fallbericht: Zwei Fälle von leptomeningealen Metastasen bei Patienten mit metastasiertem #Urothelkarzinom, die mit #EnfortumabVedotin behandelt wurden' - an @kargerpublishers.bsky.social #Oncology article on #ScienceOpen:

🔗 www.scienceopen.com/document?vid...

Fallbericht: Zwei Fälle von leptomeningealen Metastasen bei Patienten mit metastasiertem Urothelkarzinom, die mit Enfortumab Vedotin behandelt wurden

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d17219039e133"> <b>Hintergrund:</b> Die leptomeningeale Karzinomatose ist ein außergewöhnlich seltenes ...

www.scienceopen.com

June 24, 2025 at 12:14 PM

The Pharmaceutical Journal

@pharmaj.bsky.social

#RachelBrazil examines progress by researchers to create a new generation of antibody drug conjugates to improve efficacy and minimise off-target adverse effects of these cancer therapies
#Enhertu #enfortumabvedotin #antibodydrugconjugate

Engineering precision: developing the next generation of antibody drug conjugates

When results from the ‘EV-302’ bladder cancer trial were presented at the European Society for Medical Oncology annual meeting in October 2023, they received a standing ovation. The study compared…

buff.ly

January 16, 2025 at 8:30 AM

The Pharmaceutical Journal

@pharmaj.bsky.social

In this week's feature, #RachelBrazil examines a new generation of antibody drug conjugates that have been found to improve efficacy and minimise off-target adverse effects of cancer therapies

#Enhertu #enfortumabvedotin #antibodydrugconjugate

Engineering precision: developing the next generation of antibody drug conjugates

When results from the ‘EV-302’ bladder cancer trial were presented at the European Society for Medical Oncology annual meeting in October 2023, they received a standing ovation. The study compared…

buff.ly

January 19, 2025 at 6:00 PM

MedChemExpress

@medchemexpress.bsky.social

The FDA has approved #pembrolizumab or in combination with #enfortumabvedotin as perioperative treatment for adults with muscle-invasive bladder cancer (#MIBC) undergoing cystectomy.
📊KEYNOTE-B15/EV-304:
🔹Significantly improved event-free survival (EFS) and overall survival (OS)

FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa

On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab…

www.fda.gov

July 13, 2026 at 12:00 PM

Georgian Medical Journal (GMJ)

@gmj-georgia.bsky.social

New evidence in @NEJM shows perioperative combination immunotherapy (enfortumab vedotin + pembrolizumab) may improve outcomes in muscle-invasive …

#Bladdercancer #Enfortumabvedotin #Immunotherapy #NEJM #Pembrolizumab

#Bladdercancer #Enfortumabvedotin #Immunotherapy #NEJM #Pembrolizumab

https:/…